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Abstract
Background: The presence of anti-parvovirus B19 (B19V) IgM against viral capsid proteins (VP1 and VP2) has long
been used to detect recent infection. The utility of antibodies directed against B19V NS1 protein has received less
attention as a serological indicator of recent infection, although anti-B19V NS1 IgG has been associated with
persistent infection. Objecties: To elucidate the role of anti-B19V NS1 antibody detection in recent infection,
full-length B19V NS1 was expressed and purified. The resultant antigen was used to develop both Western blot assays
and microplate ELISA for the detection of NS1 antibodies. Study design: Serum specimens were obtained from
individuals recently infected with B19V (children (n=16), adults (n=40)) and from 17 individuals with no evidence
of recent B19V infection. All specimens were screened for anti-B19V NS1 IgG and IgM. Results: It was observed that
68.8% (11/16) of children recently infected with B19V were anti-B19V NS1 IgG seropositive. Furthermore, 27.5%
(11/40) anti-B19V VP2 IgM positive specimens also contained anti-B19V NS1 IgM when tested by ELISA, while no
reactivity was observed following Western blot analysis, possibly due to the absence of conformational epitopes.
Conclusions: Anti-B19V NS1 IgM detection may have utility in the confirmation of recent infection with B19V.
© 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Since its discovery in 1975, parvovirus B19
(B19V) has been identified as the causative agent
of a number of clinical conditions in humans
(Anderson et al., 1985; Kurtzman et al., 1987).
The spectrum of symptoms caused by B19V, in-
cluding rash, arthralgia and transient aplastic cri-
sis, are generally self-limiting in healthy
individuals. However, serious complications due
to viral infection may arise in certain populations
including pregnant women, immunocompromised
patients and individuals suffering from sickle cell
disease or other blood-related disorders (Jordan,
1996; To¨ro¨k, 1997).
The B19V capsid is composed of two structural
proteins, VP1 (83 kDa) and VP2 (53 kDa), with
VP2 comprising approximately 95% of total cap-
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sid protein (Ozawa and Young, 1987). Both of
these antigens have been expressed in eukaryotic
expression systems in order to assess their po-
tential use as diagnostic reagents for B19V infec-
tion (Brown et al., 1990). This work has
culminated in the recent demonstration of the
absolute requirement for intact capsid structure
for optimal detection of anti-B19V VP2 IgG
(Kerr et al., 1999).
B19V NS1 had received much less attention
as a marker of B19V infection until the pro-
posal that anti-B19V NS1 IgG may be a marker
of persistent infection (von Poblotzki et al.,
1995a,b). Recent studies have demonstrated a
range of 21.7–36% NS1 IgG seropositivity in
control subjects previously infected with B19V
(Venturoli et al., 1998; Jones et al., 1999; He-
mauer et al., 2000). An anti-B19V NS1 IgG
seropositivity of 12.5% (5/40) has been observed
in recently infected individuals, and a similarly
low rate of anti-B19V NS1 IgG positivity has
been reported in acutely infected immunocom-
petent individuals (5/43; 11%) (Jones et al.,
1999; Hemauer et al., 2000). Most of these stud-
ies on the immune response to B19V NS1 have
focused on the diagnostic utility of anti-B19V
NS1 IgG as a marker of specific B19V-related
disease or persistent infection, whereby the level
of anti-B19V NS1 IgG positivity may be as high
as 61% (24/39) and 80% (4/5), respectively, in
cases of B19V infection during pregnancy or
chronic B19V infection in immunocompetent in-
dividuals (Hemauer et al., 2000). Interestingly,
all of these studies have been performed using
E. coli expressed NS1 fragments as the detection
antigen. Furthermore, no evidence of anti-B19V
NS1 IgM has been found from specimens taken
during recent B19V infection (Hemauer et al.,
2000). A limited evaluation of baculovirus-ex-
pressed NS1 for B19V serological studies has
been reported, whereby 12% (3/25) of specimens
obtained from arthropathy patients were anti-
B19V NS1 IgG positive by Western blot analy-
sis (Hicks et al., 1996). These authors also noted
that an anti-B19V IgG positive serum pool
tested negative for anti-B19V NS1 IgM, as ex-
pected. In this study, we sought to determine
the utility of the full-length B19V NS1 protein
produced in the baculovirus expression system
for the determination of recent infection with
B19V via the analysis of anti-B19V NS1 IgG
and IgM, respectively.
2. Materials and methods
2.1. Clinical specimens
Three groups of sera were used in this study.
(i) Specimens (n=19) were obtained from chil-
dren (age range: 7–11 years) within 3 months of
a school-based outbreak of B19V infection, (ii)
anti-B19V IgM negative sera (n=17) were ob-
tained from volunteer donors exhibiting no signs
of recent B19V infection, and (iii) specimens
(n=40) that were positive for anti-B19V VP2
IgM. All sera were screened for anti-B19V IgG
and IgM by US FDA cleared in-vitro diagnostic
immunoassays (Biotrin, Dublin, Ireland).
2.2. Construction of recombinant baculoirus
encoding NS1
B19V DNA template suitable for PCR was
obtained from a B19V viremic specimen.
Primers based on the B19V sequence to include
sequences complementary to the 5 and 3 ends
of the entire 2 kb NS1 open reading frame were
selected. The 5-primer
(NSnt:GGTATGAATTCTACTTGTTAACATCC
) included an EcoRI site and the 3-primer
(NSc:CAAATTTATCATCATCACTTCTGCAGC
ATTTGCC) included a PstI site in order to fa-
cilitate the subsequent cloning of the PCR
product into the baculovirus transfer vector,
pBacPAK9 (Clontech, Palo Alto, CA) using
standard molecular biology techniques.
Spodoptera frugiperda (Sf9) insect cells were co-
transfected with recombinant transfer vector and
Bsu36 I-linearised BacPAK-6 baculovirus using
Bacfectin® liposomal preparation (Clontech).
Well plates were infected with the co-transfec-
tion mixtures and the TC-100 supernatant was
harvested after 5 days’ incubation at 27°C. A
pure clone of a recombinant baculovirus was
identified by plaque assay.
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2.3. Antigen expression and purification
Recombinant baculovirus encoding the NS1
gene was used to infect Sf9 cells in monolayer
culture at a multiplicity of infection of 2.1. In-
fected cells (5×108) were harvested 4 days post-
infection. SDS-PAGE and Western Blot were
used to confirm the presence of recombinant
B19V NS1. The cells were then lysed in the
presence of protease inhibitors (0.1 mM phenyl
methyl sulfonyl fluoride, 2 g/ml of pepstatin
and 2 g/ml of leupeptin) by the addition of
phosphate-buffered saline-0.5%(w/v) sodium de-
oxycholate. After centrifugation (3000×g for 5
min), the insoluble fraction that contained re-
combinant NS1 and nuclei was resuspended in
25 mM Hepes, 5 mM MgSO4, pH 7.4, and sub-
jected to DNase (Sigma, Poole, UK) treatment
(final concentration: 10 g/ml) for 1 h at room
temperature. Following a brief centrifugation
and wash step (3000×g for 3 min), the insolu-
ble NS1 was resuspended in 0.5–1.0 ml of 6 M
guanidinium thiocyanate at a concentration of
4–5 mg/ml and stored at −20°C.
2.4. B19V NS1 IgG Western blot
Purified NS1 was subjected to SDS-PAGE by
layering 26 g of NS1 across the stacking gel in
a final volume of 250 l of solubilisation buffer
(Laemmili, 1970). Electrotransfer onto nitrocel-
lulose was carried out according to standard
protocols except that 10 mM 3-[cyclohexy-
lamino]-1-propanesulphonic acid (CAPS), pH
10, containing 10% (v/v) methanol was used to
facilitate electrotransfer. After electrotransfer
and membrane blocking in 5% (w/v) milk pow-
der/phosphate-buffered saline–0.05% (v/v)
Tween-20® (PBST), the nitrocellulose sheets
were cut into 4 mm wide strips (1 g NS1/strip).
Specimens were diluted 1/100 in 1% (w/v) milk
powder/PBST, added to individual strips and in-
cubated for 3 h at room temperature. After a
washing step, horse-radish peroxidase (HRP)-
conjugated anti-human IgG (Dako, Glostrup,
Denmark) was added to the membrane and in-
cubated for 1 h at room temperature. Bound
antibody–conjugate complex was detected by
the addition of H2O2 and diaminobenzidine
(Sigma, Poole, UK). The band intensity was de-
termined visually, and a positive result was indi-
cated by the appearance of a band
corresponding to the position of NS1 (77 kDa).
2.5. B19V NS1-IgM enzyme immunoassay
Prior to testing all specimens were adsorbed
using anti-human IgG adsorbent (Incstar, Still-
water, MN) by adding 10 l of serum to 150 l
of adsorbent. After a brief centrifugation step
(15 000×g for 2 min), the entire supernatant
was added to 850 l of PBST (final dilution:
1/100) and mixed gently. Diluted specimens were
then added to microwells that had been previ-
ously coated with recombinant NS1 at 0.7 g/ml
in 50 mM sodium carbonate pH 9.6. Following
a 1 h incubation at room temperature and a
wash step, HRP-labelled rabbit anti-human IgM
(Sigma, Poole, UK) was added for 30 min to
detect any anti-B19V NS1 IgM present. This
complex was then detected by addition of te-
tramethyl benzidine substrate. Sulphuric acid (1
N) addition terminated the reaction after 10
min, followed by absorbance measurement at
450/630 nm. The immunoassay cut-off value was
determined by obtaining the mean absorbance
2S.D. (0.183 (2(0.077))=0.338) of a panel of
anti-B19V VP2 IgM negative specimens. Test
specimens with an index value (specimen/cut-off
value ratio) greater than 1.0 were deemed posi-
tive for anti-B19V NS1 IgM.
2.6. B19V NS1 IgM Western blot
Conditions for the detection of anti-B19V
NS1 IgM were identical to those described for
anti-B19V NS1 IgG detection, except that all
specimens were pre-treated as described for the
B19V NS1 IgM enzyme immunoassay (above)
and detected using HRP-labelled rabbit anti-hu-
man IgM (Sigma, Poole, UK).
3. Results
A single clone termed pBac11.9 was identified
that contained an insert of the appropriate size.
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Sequence analysis of pBac11.9 from the 5’- and
3’-termini using an ABI 310 Genetic analyser
(PE Applied Biosystems, Foster City, CA)
confirmed that the inserted PCR fragment
encodes the full-length open reading frame for
B19V NS1 (data not shown). For subsequent
recombinant protein work, passage two viral
stock was used to infect Sf9 cells. SDS-PAGE
and Western blot characterisation of infected
cell lysates and purified NS1 is shown in Fig. 1.
It can be seen that protein of the expected size
(77 kDa) is obtained, which is strongly
immunoreactive with human IgG [anti- B19V
NS1]. No reactivity was observed against
uninfected insect cells, although there is evidence
that limited NS1 degradation has occurred
during purification, as confirmed by the presence
of low Mr immunoreactive fragments. After
expression, it was observed that the recombinant
NS1 protein was highly insoluble and required 6
M guanidinium thiocyanate and 20 mM
dithiothreitol (DTT) to facilitate solubilisation,
but the protein remained soluble following
dialysis or dissolution, at low g/ml
concentrations, into non-denaturing buffers (e.g.
50 mM sodium carbonate pH 9.4). Protein
quantitation (Bio-Rad, Munich, Germany)
indicated a yield of 1 mg of B19V NS1 per 107
infected Sf9 cells.
Table 1
Anti-B19V IgG and IgM antibody reactivity against bac-
ulovirus-expressed VP2 and NS1 antigens
Anti-B19V NS1 IgG status
Positive Negative
10 (62.5%)Anti-B19V VP2 IgG 6 (37.5%)
positive (16)
0 (0%)Anti-B19V VP2 IgG 3 (100%)
negative (3)
Anti-B19V NS1 IgM status
NegativePositive
29 (72.5%)Anti-B19V VP2 IgM 11 (27.5%)
positive (40)
Anti-B19V VP2 IgM 16 (93%)1 (5.9%)
negative (17)
When the sera of 16 children who had been
infected with B19V 3 months earlier were
examined by Western blot, it was found that
11/16 (68.8%) contained anti-B19V NS1 IgG,
while 100% contained IgG against B19V VP2.
No anti-B19V NS1 or VP2 IgG was detected in
the sera of three seronegative children who had
not been infected during the outbreak.
When tested by B19V NS1 IgM ELISA, 11/40
(27.5%) anti-B19V VP2 IgM positive specimens
also exhibited anti-B19V NS1 IgM positivity
(Table 1). Subsequent Western blot analysis of
10 specimens (five anti-B19V NS1 IgM positive
and five anti-B19V NS1 IgM negative by
ELISA) produced a negative test result (data
not shown). Only one specimen obtained from
either clinical laboratories or laboratory
volunteers with or without previous exposure to
B19V tested anti-B19V NS1 IgM positive (Table
1). Eleven of these specimens were anti-B19V
VP2 IgG positive.
4. Discussion
Here, we report the cloning and expression of
the full-length open reading frame encoding the
NS1 protein of B19V in the baculovirus expres-
Fig. 1. Western blot analysis of baculovirus-expressed B19V
NS1. No immunoreactivity is observed in uninfected insect cell
lysate (1). Immunoreactivity is observed at the expected Mr (77
kDa) in both NS1 recombinant-baculovirus infected insect cell
lysate (2) and purified NS1 (3). Antigen visualisation was
carried out using an anti-B19V NS1 IgG positive specimen, as
described in Table 1.
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sion system. The potential diagnostic utility of the
resultant purified NS1 protein has been explored,
and it is clear that the antigen facilitates the
detection of both anti-B19V NS1 IgG and IgM
following infection with B19V. This finding offers
the possibility of using anti-B19V NS1 IgM to aid
confirmation of recent B19V infection in parallel
with anti-B19V VP2 IgM positivity and PCR
testing.
The high-level expression and purification of
intact B19V NS1 protein were achieved. No evi-
dence of NS1 cytotoxicity was observed, as has
been reported for other recombinant expression
systems used to produce the NS1 protein (von
Poblotzki et al., 1995a,b). This is most likely due
to the late protein expression obtained for any
gene under the control of the baculovirus polh
promoter in infected insect cells. The yield of
purified NS1 was between 2 and 10 mg per 108
cells, which is within the expected range for the
baculovirus expression system (O’Reilly et al.,
1994).
Initial reports suggested that the presence of
anti-B19V NS1 IgG was a strong indicator of
persistent viral infection (von Poblotzki et al.,
1995a,b). However, recent work in this area has
indicated that there may not be a significant dif-
ference between anti-B19V NS1 IgG prevalence
between individuals with either chronic or uncom-
plicated past B19V infection (Jones et al., 1999).
Interestingly, the high level of anti-B19V NS1 IgG
positivity in recently infected children observed in
the present study (68.8%) is similar to that seen
for recently infected pregnant women (61%) (He-
mauer et al., 2000). Taken together, these data
suggest that levels of anti-B19V NS1 IgG may
peak within months after infection due to NS1
presence during viral replication and then wane as
the virus is completely cleared.
Although a number of groups have undertaken
the expression of B19V NS1 in bacterial and
baculovirus expression systems, there has been no
report to date on the successful detection of anti-
B19V NS1 IgM in specimens obtained from re-
cently infected individuals (von Poblotzki et al.,
1995a,b; Hicks et al., 1996; Venturoli, 1998; He-
mauer et al., 2000). It is conceivable that the
absence of relevant conformational epitopes on
the NS1 antigens (or NS1 sub-fragments) previ-
ously employed resulted in the observed false
negative results. Alternatively, the attempted de-
tection of anti-B19V NS1 IgM in pooled speci-
mens may also have lead to the conclusion that
anti-B19V NS1 IgM is not present in previously
infected individuals (Hicks et al., 1996). We pro-
pose that the dilution of denatured and reduced
NS1 into high-pH buffer prior to microplate coat-
ing facilitates the reformation of relevant confor-
mational epitopes that are subsequently
recognised by anti-B19V NS1 IgM present in sera
obtained from certain individuals recently infected
with B19V. Evidence for this comes from the
results obtained following Western blot analysis
of anti-B19V NS1 IgM positive specimens,
whereby SDS denaturation and DTT presence
apparently lead to the disruption of conforma-
tionally relevant epitopes with concomitant false
negative detection of anti-B19V NS1 IgM.. Since
it has been previously shown that all specimens
that are anti-B19V VP2 IgM positive by mi-
croplate ELISA also test positive by Western blot
(Kerr et al., 1999), which used a similar method
for antigen electrotransfer onto nitrocellulose, it is
unlikely that methodological differences account
for the observed difference with respect to anti-
B19V NS1 IgM detection between microplate
ELISA and Western blot immunoassay. It is no-
table that no specimen tested was anti-B19V VP2
IgM negative and anti-B19V NS1 IgM positive,
which is not unexpected given the antigenic nature
of viral capsid proteins. A single specimen taken
from an individual with no recent indication of
B19V infection (Group (ii)) did test anti-B19V
NS1 IgM positive, but since this specimen also
exhibited strong IgG reactivity against B19V VP2,
it is likely to represent a false positive reaction in
the B19V NS1 IgM immunoassay.
It should now be possible to further utilise
baculovirus-expressed recombinant NS1 to deter-
mine the seroprevalence of anti-B19V NS1 IgG in
selected population groups, particularly in re-
cently infected, immunocompetent individuals to
confirm the high prevalence of anti-B19V NS1
IgG in recent infection. Significantly, Kaikkonen
et al. (1999) have recently identified a specific
heptapeptide epitope in B19V VP2 which is recog-
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nised by patients with acute or recent infection.
Thus, it is tempting to speculate that anti-B19V
NS1 IgG reactivity against specific B19V NS1
epitopes could be used, in association with anti-
body detection of linear epitopes on B19V VP2,
as a marker of recent infection. Finally, the asso-
ciation between anti-B19V NS1 IgM detection
and infection with specific isolates of B19V and
putative associated pathogenicities, in both im-
munocompetent and immunocompromised indi-
viduals, also merits further investigation.
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